Var2 Pharmaceuticals Aps

Zymeworks Inc.

Mads Daugaard

Madeleine Dahlback

Ali Salanti

Thor Grundtvig Theander

Morten Nielsen

Thomas Mandel Clausen

John Stephen Babcook

James R Rich

Ali El-Salanti

Geoffrey C Winters

Tom Han Hsiao Hsieh

Alexander Laurence Mandel

Bradley John Hedberg

Elyse Marie Josée Bourque

Elyse Marie Bourque

Tom Han Hsieh

Alexander L Mandel

Tom Han Hsiao Hsie

Madeleine DAHLBÄCK

The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

Targeting of chondroitin sulfate glycans

VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.

VAR2CSA-drug conjugates

VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.

Compositions and methods for the treatment of platinum-drug resistant cancer

Growing community of inventors

Vancouver, Canada

Mads Daugaard